Not Yet Recruiting PHASE4 INTERVENTIONAL 2-arm
NCT07093931
Efficacy and Safety of Lobaplatin and Carboplatin as Neoadjuvant Therapy in HER-2 Positive Breast Cancer
A Phase Ⅲ Study to Evaluate Efficacy and Safety of Lobaplatin and Carboplatin as Neoadjuvant Therapy in Participants With HER-2 Positive Breast Cancer.
Sponsor: Cancer Hospital Chinese Academy of Medical Science
Conditions
Breast Cancer
Updated 1 time since 2025 Last updated: Jul 22, 2025 Started: Aug 1, 2025 Primary completion: Aug 1, 2027 Completion: Aug 1, 2030
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
Listed as NCT07093931, this PHASE4 trial focuses on Breast Cancer and remains actively recruiting participants. Sponsored by Cancer Hospital Chinese Academy of Medical Science, it has been updated 1 time since 2025, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
1 version recorded Not Yet Recruiting — PHASE4
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Cancer Hospital Chinese Academy of Medical Science
- Shandong Cancer Hospital and Institute
Data source: Shandong Cancer Hospital and Institute
For direct contact, visit the study record on ClinicalTrials.gov .